BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12722677)

  • 1. [Hematopoietic malignancies and gene therapy].
    Ozawa K
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
    Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicine. Gene therapy--new challenges ahead.
    Williams DA; Baum C
    Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy resumes.
    Novak K
    Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
    Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
    Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotoxicity of retroviral integration in hematopoietic cells.
    Nienhuis AW; Dunbar CE; Sorrentino BP
    Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
    Kang EM; Tisdale JF
    Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress toward the genetic treatment of the beta-thalassemias.
    Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
    Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancer case halts gene-therapy trials.
    Check E
    Nature; 2003 Jan; 421(6921):305. PubMed ID: 12540867
    [No Abstract]   [Full Text] [Related]  

  • 11. Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes.
    Junker K; Koehl U; Zimmerman S; Stein S; Schwabe D; Klingebiel T; Grez M
    Gene Ther; 2003 Jul; 10(14):1189-97. PubMed ID: 12833128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
    N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
    [No Abstract]   [Full Text] [Related]  

  • 16. Manipulation of the stem cell as a target for hematologic malignancies.
    Ballen KK; Becker PS; Stewart FM; Quesenberry PJ
    Semin Oncol; 2000 Oct; 27(5):512-23. PubMed ID: 11049019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV vector-mediated targeted suicide gene therapy for adult T-cell leukemia.
    Miyake K; Inokuchi K; Miyake N; Dan K; Shimada T
    Gene Ther; 2007 Dec; 14(23):1662-7. PubMed ID: 17898798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and benefits of gene therapy.
    Noguchi P
    N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
    [No Abstract]   [Full Text] [Related]  

  • 20. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
    McCormack MP; Rabbitts TH
    N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.